69 Best Biotech Startups to Watch in 2024
How do we build this list? TLDR: Using math and experts.
Last update to the database: May 26, 2024. See changelog.
Join 23,000+ founders, operators and investors.
Seedtable Score Learn how we calculate it here
Sign up to Seedtable Intel to access the entire database
company | score | funding | investors | employees | industries | biz model | city | contact |
---|---|---|---|---|---|---|---|---|
Antibody-Drug Conjugate specialist creating treatments for tough-to-treat cancers. |
$120M · Series B | TCG Crossover, Atlas Ventures, Brandon Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@pheontx.com | |
Developer of treatment for diffuse tenosynovial giant cell tumors. |
$75M · Series B | Bioqube Ventures, Medicxi, Forbion Capital Partners | 1 to 10 | Health Tech, Biotech | B2B | Dublin, Ireland | •••••••••••@synoxtherapeutics.com | |
Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. |
$139M · Series B | Nextech Invest, EQT Life Sciences, Andera Partners | 11 to 50 | Health Tech, Biotech, Deep Tech | B2B | Munich, Germany | •••••••••••@tubulis.com | |
Provider of single and multi-organ microphysiological systems. |
$21M · Series B | CN Innovations | 101 to 250 | Health Tech, Biotech | London, UK | •••••••••••@cn-bio.com | ||
AI-driven intronization technology developer. |
$13M · Seed | Octopus Ventures, Acequia Capital, Redalpine | 1 to 10 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@expressionedits.com | |
Drug discovery platform. |
$32M · Series A | Wendel Growth, Bpifrance, Elaia | 51 to 100 | Biotech | B2B | Paris, France | •••••••••••@aqemia.com | |
Biomedical research discovery tool. |
$60M · Series B | ICONIQ Growth, Index Ventures, Pentech Ventures | 51 to 100 | Health Tech, AI, Biotech, Pharma | B2B, SaaS | London, UK | •••••••••••@causaly.com | |
Oophthalmic gene therapy company to treat blinding retinal illnesses. |
$120M · Series A | Syncona Partners LLP | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@beacontx.com | ||
Portfolio of pharmaceutical research and discovery. |
$33M · Series C | Patient Square Capital, Rock Springs Capital, M&G Investments | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@apollotherapeutics.com | ||
Gene-editing platform. |
$30M · Series B | Khosla Ventures, Sanofi Ventures, Bpifrance | 11 to 50 | Health Tech, Biotech | Paris, France | •••••••••••@eligo.bio | ||
Immunotherapies developer for cancer patient. |
$4M · Seed | Fournier-Majoie, France 2030, Elaia | 1 to 10 | Health Tech, Biotech | Paris, France | •••••••••••@hephaistos-pharma.fr | ||
Developer of a universal AI foundation model for biology. |
$35M · Seed | Frst, Bpifrance, Sofinnova Partners | 1 to 10 | AI, Biotech | B2B, SaaS | Paris, France | •••••••••••@bioptimus.com | |
Cancer survivors data analysis platform. |
$16M · Seed | Hitachi Ventures, Life Extension Ventures, Sofinnova Partners | 11 to 50 | Biotech, Data and Analytics | B2B, SaaS | Paris, France | •••••••••••@cure51.com | |
Precision oncology treatments developer. |
$21M · Series A | V-Bio Ventures | 1 to 10 | Health Tech, Biotech | Amsterdam, Netherlands | •••••••••••@flindrtx.com | ||
Developer of next-generation T cells against solid tumors. |
$9M · Seed | Brandenburg Kapital, i&i Biotech Fund | 1 to 10 | Health Tech, Biotech | Berlin, Germany | •••••••••••@captaintcell.com | ||
Antibody-drug conjugates (ADCs) developer for the treatment of cancer. |
$17M · Series A | RA Capital Management, Novo A/S, HealthCap | 11 to 50 | Health Tech, Biotech | B2B | Copenhagen, Denmark | •••••••••••@adcendo.dk | |
Eco-friendly liquid-liquid direct lithium extraction (DLE) process developer. |
$27M · Series B | Bpifrance, Celeste Management, Sociedad Quimica Y Minera (SQM) | 11 to 50 | Climate Tech & Green Tech, Biotech | B2B | Paris, France | •••••••••••@adionics.com | |
AI vaccine algorithm developer. |
$11M · Series A | Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures | 1 to 10 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@baseimmune.co.uk | |
Biotechnology firm focused on life science advancements. |
$89M · Series A | Sofinnova Partners | 101 to 250 | Health Tech, Biotech | B2B | Paris, France | •••••••••••@mnemo-tx.com | |
Bio-identical egg protein producer. |
$15M · Series A | EIT Food, Agronomics, EIC Accelerator | 11 to 50 | Foodtech, Biotech | B2C | Helsinki, Finland | •••••••••••@onego.bio | |
Biotechnology company focused on developing genomic medicines to treat blinding inherited retinal diseases. |
$52M · Series A | Ysios Capital | 1 to 10 | Health Tech, Biotech, Deep Tech | B2B | Paris, France | •••••••••••@sparingvision.com | |
Active ingredient producer from plant stem cells for the cosmetics industry. |
$2M · Seed | Boyser SRL, ICF Capital | 11 to 50 | Biotech, Manufacturing | B2B | Barcelona, Spain | •••••••••••@vytrus.com | |
Preclinical stage treatment for geographic atrophy. |
$78M · Series A | Forbion Capital Partners, Gimv | 1 to 10 | Biotech | London, UK | •••••••••••@complementtx.com | ||
Discovery and development platform of superior microbial bioproducts. |
$6M · Series A | Pymwymic, Clean Growth Fund | 1 to 10 | Biotech | London, UK | •••••••••••@fungialert.com | ||
Developer of therapies for inflammatory and fibrotic diseases. |
$81M · Series A | Sarsia, p53, Forbion Capital Partners | 11 to 50 | Biotech, Pharma | Oslo, Norway | •••••••••••@callunapharma.com | ||
AI platform to map the human immune system. |
$14M · Series A | Molten Ventures, Life Extension Ventures | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@imubiosciences.com | ||
Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies. |
$8M · Series A | Mercia Asset Management | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@mipdiscovery.com | ||
Neuroscience-driven AI platform. |
$2M · Seed | Rockmount Capital, Moonfire Ventures, UCL Technology Fund | 11 to 50 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@stanhopeai.com | |
Biosensors developer to combat chronic kidney disease. |
$2M · Pre Seed | Bpifrance, Kima Ventures, Cenitz | 1 to 10 | Health Tech, Biotech | Paris, France | •••••••••••@metyos.com | ||
Advanced allosteric modulator therapeutics developer for neurological disorders. |
$63M · Series A | Xontogeny, Perceptive Advisors, Acorn Bioventures | 1 to 10 | Health Tech, Biotech | Geneva, Switzerland | •••••••••••@neurosterix.com | ||
Developer of sustainable plant-based pigments. |
$3M · Seed | PDS Ventures, Circular Innovation Fund, L'Oreal | 1 to 10 | Biotech, Manufacturing | B2C | London, UK | •••••••••••@sparxell.com | |
Point-of-care diagnostic platform. |
$1M · Pre Seed | CentraleSupélec Venture | 1 to 10 | Health Tech, Biotech | Paris, France | •••••••••••@encarta.bio | ||
Innovative immunotherapies developer for cancer patients. |
$150M · Series D | Brandon Capital, Bioqube Ventures, Forbion Capital Partners | 11 to 50 | Health Tech, Biotech | B2B | Munich, Germany | •••••••••••@catalym.com | |
Platform using deep learning on 3D molecular structures to develop treatments for harmful proteins. |
$50M · Series A | Khosla Ventures, General Catalyst | 1 to 10 | Health Tech, AI, Biotech, Data and Analytics | B2B | London, UK | •••••••••••@charmtx.com | |
Biotechnology firm developing immunotherapies for cancer and autoimmune diseases. |
$46M | Bioqube Ventures | 11 to 50 | Health Tech, Biotech | B2B | Paris, France | •••••••••••@egle-tx.com | |
Platform that develops bio factories to treat significant eye diseases sustainably. |
$30M · Series B | Karista, Pureos Bioventures | 11 to 50 | Health Tech, Hardware, Biotech, Manufacturing | B2B | Paris, France | •••••••••••@eyevensys.com | |
Clinical trials platform. |
$18M · Series A | Valar Ventures, Creandum, Seedcamp | 11 to 50 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@lindushealth.com | |
Developer of prophylactic vaccine against Group B Streptococcus. |
$57M · Series C | EQT Partners, Novo A/S, OrbiMed | 1 to 10 | Health Tech, Biotech | B2B | Copenhagen, Denmark | •••••••••••@minervax.com | |
Fully-automated cell manufacturing. |
$19M · Series A | Buckley Ventures, Wing Venture Capital, IQ Capital Partners | 11 to 50 | Biotech, Machine Learning | B2B | London, UK | •••••••••••@mytos.bio | |
Oral macrocycle drug discovery platform. |
$28M · Seed | Novo A/S, Forbion Capital Partners | 1 to 10 | Health Tech, Biotech | B2B | Copenhagen, Denmark | •••••••••••@orbismedicines.com | |
Manufacturing platform designed to help patients access lifesaving treatments. |
$30M · Series A | Kindred Capital, Octopus Ventures, Amadeus Capital | 1 to 10 | Health Tech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@oribiotech.com | |
Cell therapy firm specializing in developing treatments using advanced cellular technology. |
$45M · Series A | AlbionVC, Point72 Ventures | 101 to 250 | Health Tech, Edtech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@quell-tx.com | |
Biotechnology firm developing antiviral treatments for patients. |
$44M · Series C | Novo A/S, Andera Partners | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@reviral.co.uk | |
Platform specializing in developing new, high-yield tropical crop varieties and traits. |
$28M · Series B | Future Planet Capital | 11 to 50 | Agritech, Biotech, Deep Tech, Manufacturing | B2B | London, UK | •••••••••••@tropicbioscience.com | |
Fat ingredient producer for alternative meats. |
$2M · Seed | b.value AG, Life Science Valley Wachstumsfond, Kale United | 1 to 10 | Foodtech, Biotech | B2B | Berlin, Germany | •••••••••••@cultimatefoods.com | |
Fermentation process to produce protein from animals. |
$5M · Seed | Voyager Ventures, Revent, World Fund | 1 to 10 | Foodtech, Biotech | B2C | Amsterdam, Netherlands | •••••••••••@farmless.com | |
Gene therapies for inherited retinal disorders. |
$65M · Series A | Forbion Capital Partners | 1 to 10 | Biotech | Milan, Italy | •••••••••••@aavantgardebio.com | ||
Automated bioprocessing system for the production of cell and gene therapies. |
$18M · Seed | AdBio Partners | 11 to 50 | Biotech | Paris, France | •••••••••••@astraveus.com | ||
Platform to automate the clinical studies process. |
$12M · Series A | Playfair, Delin Ventures, 11.2 Capital | 11 to 50 | Health Tech, Biotech | B2B | London, UK | •••••••••••@umed.io | |
Patent-protected anti-inflammatory painkiller. |
$6M · Series A | ITV AdVentures | 1 to 10 | Biotech, Pharma | B2C | London, UK | •••••••••••@flarin.co.uk | |
User-owned genomics database platform. |
$20M · Series A | GEM Digital | 1 to 10 | Health Tech, Biotech | B2C | London, UK | •••••••••••@genomes.io | |
Medical devices for a transvascular treatment of pulmonary hypertension. |
$14M · Series A | Sofinnova Partners, Asabys Partners | 1 to 10 | Health Tech, Biotech | Paris, France | •••••••••••@gradientdenervation.com | ||
Gene silencing platform for the creation of programmable, allogeneic cell therapies. |
$16M · Seed | Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@laverocktx.com | ||
Biomanufacturer of complex molecules. |
$4M · Seed | Meusinvest (Noshaq) | 1 to 10 | Biotech, Manufacturing | Paris, France | •••••••••••@samabriva.com | ||
Therapeutic protein developer for chronic neuropathic pain. |
$24M · Series A | Medical Incubator Japan, Borean Innovation, Novo A/S | 1 to 10 | Health Tech, Biotech | Copenhagen, Denmark | •••••••••••@hobatherapeutics.com | ||
Medicine for rare neurological diseases. |
$58M · Series B | Droia Ventures, Ackermans & van Haaren, Idinvest Partners | 11 to 50 | Health Tech, Biotech | B2C | The Hague, Netherlands | •••••••••••@vicotx.com | |
Polyhydroxyalkanoates (PHA) producer. |
$15M · Seed | NV NOM, Invest-NL | 1 to 10 | Biotech | Amsterdam, Netherlands | •••••••••••@paquesbiomaterials.nl | ||
Cloud-native chemical simulation platform. |
$3M · Seed | Chemovator, Ananda Impact Ventures, IBB Ventures | 11 to 50 | Biotech, Cloud | B2B, SaaS | Berlin, Germany | •••••••••••@quantistry.com | |
Sustainable corrosion inhibitors manufacturer. |
$1M · Seed | Oxford Innovation Finance, Waterspring Ventures, Development Bank of Wales | 1 to 10 | Biotech, Manufacturing | B2B | London, UK | •••••••••••@hexigone.com | |
Gene therapy platform. |
$6M · Seed | Life Extension Ventures, Zühlke Group, Oxford Seed Fund | 1 to 10 | Health Tech, Biotech | Geneva, Switzerland | •••••••••••@limula.ch | ||
Viral vector-based cancer vaccines developer. |
$82M · Series C | Bpifrance, 5AM Ventures, Abingworth | 1 to 10 | Health Tech, Biotech | B2C | Basel, Switzerland | •••••••••••@nouscom.com | |
Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. |
$17M · Seed | AlbionVC, Boxer Capital, Syncona Partners LLP | 101 to 250 | Health Tech, Biotech | B2B | London, UK | •••••••••••@achillestx.com | |
Early detection of Alzheimer's disease (AD) technology. |
$5M · Series A | WA4STEAM, EIC Accelerator, Ship2B | 1 to 10 | Health Tech, Biotech, Pharma | B2B | Barcelona, Spain | •••••••••••@admit-therapeutics.com | |
Developer of bio-fabricated silk protein materials. |
$27M · Series C | Novo A/S | 11 to 50 | Health Tech, Biotech, Manufacturing | B2B | Munich, Germany | •••••••••••@amsilk.com | |
Diagnosis and treatment of hard-to-treat cancers. |
$24M · Series A | Earlybird Venture Capital, Andera Partners, HealthCap | 11 to 50 | Health Tech, Biotech, Pharma | B2B | Berlin, Germany | •••••••••••@ariceum-therapeutics.com | |
Producer of gut health binding proteins. |
$32M · Series A | Bill & Melinda Gates Foundation, Novo A/S | 1 to 10 | Biotech, Pharma | B2B | Copenhagen, Denmark | •••••••••••@bactolife.com | |
Gynecological health company creating products and services for vaginal treatment. |
$5M · Seed | Khosla Ventures, Index Ventures, Kindred Capital | 11 to 50 | Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis | B2C | London, UK | •••••••••••@yourdaye.com | |
Bio alternative to fossil-based and energy–intensive chemical production. |
$22M · Series B | Sofinnova Partners, SEB Venture Capital, Industrifonden | 51 to 100 | Health Tech, Biotech | B2B | Stockholm, Sweden | •••••••••••@enginzyme.com | |
Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases. |
$3M · Series F | The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science | 51 to 100 | Health Tech, Biotech, Deep Tech, Pharma | B2B | Paris, France | •••••••••••@enterome.com |
Sign up to access our full database
Enter your email and get access to 18,000+ technology companies you can partner with – 992 in Biotech.
- Manufacturing... (2541)
- Health Tech... (2480)
- Fintech... (2445)
- Ecommerce... (1779)
- AI... (1630)
- Mobile... (1588)
- Data and Analytics... (1511)
- Business Intell...... (1461)
- Hardware... (1219)
- Climate Tech & ...... (1100)
- Energy & Nuclear... (1010)
- Biotech... (993)
- Mobility & Tran...... (948)
- Sales and Marke...... (947)
- Foodtech... (927)
- Proptech & Real...... (913)
- Deep Tech... (810)
- Media and Enter...... (787)
- Crypto & web3... (703)
- Edtech... (660)
- CPG & Consumer ...... (619)
- Developer Tools... (518)
- Privacy and Sec...... (515)
- Gaming... (497)
- Payments... (496)
- Machine Learning... (475)
- Hiring and Recr...... (473)
- Communications... (469)
- Fashion... (433)
- Community & Lif...... (405)
- Travel Tech... (392)
- Agritech... (389)
- Adtech... (374)
- Legal Tech... (358)
- Sportstech... (357)
- Cybersecurity... (295)
- Consumer Social... (293)
- Supply Chain & ...... (281)
- Video... (280)
- Pharma... (278)
- Robotics... (277)
- Productivity Tools... (257)
- Creative Tools... (256)
- Enterprise Soft...... (255)
- Insuretech... (231)
- CRM... (217)
- AR / VR... (214)
- Internet of Things... (213)
- Future of Work... (210)
- Music and Audio... (199)
- Fitness... (191)
- Cloud... (190)
- Service Industry... (162)
- Investing... (138)
- Food Delivery... (138)
- Space Tech... (137)
- Wearables... (111)
- Identity Manage...... (92)
- Navigation and ...... (84)
- Electric Vehicles... (81)
- Publishing... (77)
- ElderTech... (73)
- Govtech... (71)
- Semiconductor... (69)
- Personal Finance... (67)
- Art... (66)
- Drones... (66)
- Messaging... (63)
- Open Source... (57)
- IT Management... (53)
- Pet Tech... (51)
- Quantum Computing... (50)
- FamilyTech & Pa...... (44)
- Esports... (34)
- Genetics... (28)